治疗性HNF4A mRNA在临床前模型中减轻肝纤维化
本研究探讨了通过mRNA递送恢复人肝细胞核因子α(HNF4A)对肝纤维化和肝硬化的治疗作用。在体外,HNF4A mRNA转染可恢复纤维化原代小鼠和人肝细胞的代谢活性;在体内,重复递送封装HNF4A mRNA的肝细胞靶向可生物降解脂质纳米颗粒(LNPs)在4种独立的小鼠肝毒性及胆汁淤积诱导的肝纤维化模型中强烈抑制纤维生成。机制上,对氧磷酶1是HNF4A的直接靶标,通过调节肝脏巨噬细胞和肝星状细胞参与HNF4A介导的肝纤维化减轻。
要点
- HNF4A mRNA可恢复纤维化原代小鼠和人肝细胞的代谢活性。
- LNP封装HNF4A mRNA在4种小鼠肝纤维化模型中抑制纤维生成。
- 对氧磷酶1是HNF4A直接靶标,介导肝纤维化减轻。
核心结论
- 研究首次提供临床前直接证据,表明HNF4A mRNA疗法可用于治疗肝纤维化。
研究设计与样本
- 在体外用HNF4A mRNA转染纤维化原代小鼠和人肝细胞,并在多种小鼠肝纤维化和肝硬化模型中递送封装HNF4A mRNA的肝细胞靶向可生物降解LNPs。
主要发现
- HNF4A mRNA表达恢复了纤维化原代小鼠和人肝细胞的代谢活性。
- 重复体内递送LNP封装HNF4A mRNA在4种独立的小鼠肝毒性及胆汁淤积诱导的肝纤维化模型中强烈抑制纤维生成。
- 对氧磷酶1是HNF4A的直接靶标,通过调节肝脏巨噬细胞和肝星状细胞参与HNF4A介导的肝纤维化减轻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Therapeutic targeting of injuries that require transient restoration of proteins by mRNA delivery is an attractive approach that, until recently, has remained poorly explored. In this study, we examined the therapeutic utility of mRNA delivery for liver fibrosis and cirrhosis. Specifically, we aimed to demonstrate the therapeutic efficacy of human hepatocyte nuclear factor alpha (HNF4A) mRNA in mouse models of fibrosis and cirrhosis. METHODS: We investigated restoration of hepatocyte functions by HNF4A mRNA transfection in vitro, and analyzed the attenuation of liver fibrosis and cirrhosis in multiple mouse models, by delivering hepatocyte-targeted biodegradable lipid nanoparticles (LNPs) encapsulating HNF4A mRNA. To identify potential mechanisms of action, we performed microarray-based gene expression profiling, single-cell RNA sequencing, and chromatin immunoprecipitation. We used primary liver cells and human liver buds for additional functional validation. RESULTS: Expression of HNF4A mRNA led to restoration of the metabolic activity of fibrotic primary murine and human hepatocytes in vitro. Repeated in vivo delivery of LNP-encapsulated HNF4A mRNA induced a robust inhibition of fibrogenesis in 4 independent mouse models of hepatotoxin- and cholestasis-induced liver fibrosis. Mechanistically, we discovered that paraoxonase 1 is a direct target of HNF4A and it contributes to HNF4A-mediated attenuation of liver fibrosis via modulation of liver macrophages and hepatic stellate cells. CONCLUSION: Collectively, our findings provide the first direct preclinical evidence of the applicability of HNF4A mRNA therapeutics for the treatment of fibrosis in the liver. LAY SUMMARY: Liver fibrosis and cirrhosis remain unmet medical needs and contribute to high mortality worldwide. Herein, we take advantage of a promising therapeutic approach to treat liver fibrosis and cirrhosis. We demonstrate that restoration of a key gene, HNF4A, via mRNA encapsulated in lipid nanoparticles decreased injury in multiple mouse models of fibrosis and cirrhosis. Our study provides proof-of-concept that mRNA therapy is a promising strategy for reversing liver fibrosis and cirrhosis.
引用
- Yang T, Poenisch M, Khanal R, et al. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol. 2021. PMID: 34453962. doi:10.1016/j.jhep.2021.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。